Figure 2

Effects of preventive treatment on DNBS-induced tissue damage and inflammation. Assessments of (A) bowel thickness, (B) bowel length, (C) MPO activity, and (D) lipocalin in feces in control groups (PBS-glycerol, DNBS) and treatment groups (LL-Probi-H1:empty, LL-Probi-H1:hCAP18, LL-pSEC:empty, LL-pSEC:hCAP18). Data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n = n = 24 mice per group for LL-Probi-H1:empty and LL-Probi-H1:hCAP18, n = 16 for LL-pSEC:empty and LL-pSEC:hCAP18, n = 20 mice for healthy control.